MIRA•benzinga•
EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study
Summary
MIRA's Ketamir-2 shows promise in treating diabetic neuropathy, with a Phase 2a trial expected by late 2025 and human data in early 2026.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 16, 2025 by benzinga